Different NT-proBNP circulating levels for different types of cardiac amyloidosis

Journal of Cardiovascular Medicine
Federico PerfettoFrancesco Cappelli

Abstract

Several studies suggest that the N-terminal fragment of pro-brain natriuretic peptide levels are quite different in wild-type transthyretin (TTR)-related amyloidosis (ATTRwt) and mutated TTR-related amyloidosis (ATTRm) compared with immunoglobulin light-chain cardiac amyloidosis. Our aim was to test this hypothesis in a cohort of patients with different types of cardiac amyloidosis. Seventy patients with ATTRwt, ATTRm, and light-chain cardiac amyloidosis matched for left ventricular (LV) mass index were studied by standard echocardiography, tissue Doppler imaging, and plasmatic cardiac biomarkers. Despite similar LV mass and renal function, patients with ATTR cardiac amyloidosis showed lower levels of N-terminal fragment of pro-brain natriuretic peptide than do light-chain amyloidosis ones, especially when expressed as a function of LV mass index. Amyloidogenic light-chain-derived fibrils induce more severe myocardial dysfunction in light-chain amyloidosis than in ATTR, despite similar myocardial infiltration. Thus, the degree of cardiac dysfunction may be related not only to the amount of amyloid deposited, but also to qualitative differences among fibrils.

References

Jun 1, 1992·Journal of the American College of Cardiology·A GanauJ H Laragh
Apr 3, 1998·Journal of the American College of Cardiology·G TakemuraH Fujiwara
May 14, 1998·QJM : Monthly Journal of the Association of Physicians·S W DubreyR H Falk
Sep 20, 2005·Journal of the American College of Cardiology·Enrica PeruginiClaudio Rapezzi
Sep 28, 2005·Circulation·Rodney H Falk
Feb 7, 2006·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Roberto M LangUNKNOWN European Association of Echocardiography, European Society of Cardiology
Dec 12, 2007·Journal of Internal Medicine·O B SuhrA Waldenström
Feb 13, 2008·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Claudio RapezziAngelo Branzi
Mar 18, 2009·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Merrill D BensonJuris J Liepnieks
Nov 20, 2009·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Stephanie LehrkeEvangelos Giannitsis
Jul 9, 2011·Internal and Emergency Medicine·Federico PerfettoAlberto Moggi Pignone
Jan 15, 2014·JACC. Cardiovascular Imaging·Marianna FontanaJames C Moon
Jun 19, 2014·European Heart Journal Cardiovascular Imaging·David F HuttAshutosh D Wechalekar

❮ Previous
Next ❯

Citations

Jun 21, 2019·Open Heart·Stéphanie BrunUNKNOWN Toulouse Amyloidosis Research Network collaborators
Feb 19, 2017·Clinical Science·Natalie J GalantAvijit Chakrabartty
Nov 30, 2019·Current Heart Failure Reports·Sandra IhneStefan Störk
Feb 8, 2021·JACC. Heart Failure·Silvia OghinaDiane Bodez
Feb 3, 2021·European Journal of Heart Failure·Vincenzo CastiglioneGiuseppe Vergaro
May 7, 2020·IJC Heart & Vasculature·Maria PapathanasiouPeter Luedike
Jul 13, 2020·JACC. Heart Failure·Arianna Pregenzer-WenzlerJose Nativi-Nicolau
Sep 23, 2021·Arquivos brasileiros de cardiologia·Marcus V SimõesEvandro Tinoco Mesquita

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies
electron microscopy
coronary artery bypass

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.